Cost of hospital care for refugees and migrants and the situation regarding pharmaceutical companies
6.7.2016
Question for written answer E-005527-16
to the Commission
Rule 130
Georgios Kyrtsos (PPE) , Elissavet Vozemberg-Vrionidi (PPE)
Greece is the principal beneficiary of aid from the Asylum, Migration and Integration Fund (AMIF) and the Internal Security Fund (ISF), amounting to around EUR 509 million for the period 2014-2020.
However, at the end of June 2016, pre-financing of EUR 70 million had, according to the Commission, remained unused by Greece.
In addition to this delay, Greek public hospitals are now, in the necessary spirit of solidarity, providing medical care for thousands of migrants and refugees, the cost of which is being met by Greek taxpayers and by pharmaceutical companies, which are required to pay excessive amounts under the agreed claw-back provisions.
In view of this:
- 1.What measures could the Commission take to secure funding for the medical treatment of refugees and migrants in Greek public hospitals?
- 2.Could AMIF and ISF appropriations be earmarked for national framework healthcare provisions benefiting refugees and migrants in particular?
- 3.How will the Commission seek to persuade the Greek Government to achieve a 30% claw-back reduction in 2017 and 2018 under the provisions of the third programme?